Astellas sells off diabetes IP for $609M; Valeant snaps up Meda drug rights;

@FiercePharma: Icahn sues Forest for info on Solomon's woes. News | Follow @FiercePharma

> Astellas Pharma, Japan's No. 2 drugmaker, said it is selling diabetes-related patents to a fund for $609 million, which would then be invested in strategic initiatives. Report

> Canada's Valeant Pharmaceuticals acquired rights to market skin medicines Elidel and Xerese in the U.S., Canada and Mexico from Sweden's Meda for $76 million up front and up to $130 million over the next 18 months, plus longer-term royalties. Article

> Danish drugmaker Lundbeck will continue to sell a drug used in U.S. executions because pulling it off the market would be bad for some patients with severe epilepsy, its CEO said. News

> A U.S. court ordered the seizure of a pet drug made by pharmaceutical companies Cipla and Velcera, after ruling the drug violated a Sanofi unit's patent. Story

> Pfizer's Japanese subsidiary has begun commercial operations at a new established products division, through which it will more actively promote and develop its portfolio of older drugs. News

> Now that the U.S. Supreme Court has struck down a Vermont law that restricted the sale of prescribing information for marketing purposes, a similar law in Maine is now being sent back to a federal appeals court for judicial review. Report

> Merck's animal health division, formerly known as Intervet/Schering-Plough Animal Health, announced that it will begin using its new name, Merck Animal Health. News

> Canada's federal and provincial governments are now taking more than two and a half years, on average, to approve new prescription medicines, a new report says. Story

> Latvian pharmaceutical company Grindeks has opened a new API manufacturing plant that it predicts will add around €10 million to its annual turnover when operating at full capacity. Article

> Canada's Cipher Pharmaceuticals said Vertical Pharmaceuticals will exclusively market and distribute its drug to treat chronic pain in adults in the U.S. Report

> The deadline for implementation of a bar-code system on India's pharmaceutical exports is likely to be extended further. Item

> A third of patients with diabetes admit to regularly missing or not taking insulin treatment three days a month, according to a new poll. Story

Biotech News

@FierceBiotech:  Though widely endorsed, deals may not be R&D panacea. News | Follow @FierceBiotech 

@JohnCFierce: Lechleiter tells Reuters he's sticking to R&D budget. Investors thinking of R&D cuts? "kind of nuts." Item | Follow @JohnCFierce

> Novartis Venture Fund leads $36M raise for Sorbent. Story

> Astellas' patent sale gins $609M for new round of dealmaking. News 

> Third Rock launches new rare-disease biotech with $26M round. Report  

Vaccines News

> Transitioning to human models a big obstacle for DNA cancer vaccines. News

> Merck's Gerberding discusses advantages, challenges of vaccines. Report

> Type 1 diabetes vaccine flunks trial. Article

> Collaborations are key in vaccine industry. Item

Manufacturing News

> Brown prods FDA on foreign API link with drug shortages. Item

> DHL, BT team for RFID-secure supply chain. News 

> Musty odor drives another Tylenol recall. Article

> Baxter gets warned on missing field reports. Story

> Expansion-minded Almac stays on task. News

> Merck, UPS grow closer in expanded logistics deal. Report

And Finally... With a technological crystal ball--a.k.a. fMRI scans--scientists predicted future actions based on brain activity. Piece